274 studies found for:    United States, Texas | United States, Texas | cook children's
Show Display Options
Rank Status Study
21 Completed A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Conditions: Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: Azacitidine;   Drug: Fludarabine;   Drug: Cytarabine
22 Active, not recruiting Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Long-term Effects Secondary to Cancer Therapy in Children;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: diffusion tensor imaging;   Other: laboratory biomarker analysis;   Other: pharmacological study
23 Active, not recruiting Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
Conditions: Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Spinal Cord Neoplasm;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat;   Biological: bevacizumab;   Drug: temozolomide
24 Recruiting Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Conditions: Childhood Hepatoblastoma;   Stage I Childhood Liver Cancer;   Stage II Childhood Liver Cancer;   Stage III Childhood Liver Cancer;   Stage IV Childhood Liver Cancer
Interventions: Procedure: therapeutic conventional surgery;   Drug: cisplatin;   Drug: fluorouracil;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Drug: temsirolimus;   Procedure: liver transplantation;   Other: laboratory biomarker analysis
25 Active, not recruiting Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
26 Completed Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Childhood Hepatoblastoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: alisertib;   Other: pharmacological study;   Other: laboratory biomarker analysis
27 Recruiting Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Condition: Recurrent Neuroblastoma
Interventions: Drug: temozolomide;   Drug: irinotecan hydrochloride;   Drug: temsirolimus;   Biological: dinutuximab;   Biological: sargramostim;   Other: laboratory biomarker analysis
28 Active, not recruiting Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Condition: Bronchopulmonary Dysplasia
Interventions: Drug: Inhaled Nitric Oxide;   Drug: Placebo
29 Recruiting Pediatric Obesity Weight Evaluation Registry (POWER) Study
Conditions: Overweight;   Obesity
Intervention:
30 Recruiting Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: isotretinoin;   Biological: sargramostim;   Biological: dinutuximab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: pharmacological study
31 Recruiting IGIV Study for Chronic ITP Patients Ages 3-70
Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Biological: IGIV3I Grifols 10%
32 Recruiting Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Conditions: Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
Interventions: Other: Anthropometry;   Other: Serum Biomarkers;   Other: Diagnostic/symptom checklist;   Procedure: Echocardiogram;   Other: 6 minute walk test (6MWT);   Behavioral: Participant Questionnaires (ages >14 years only)
33 Active, not recruiting Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
Conditions: Childhood Absence Epilepsy;   Petit Mal Epilepsy;   Epilepsy;   Seizures
Interventions: Drug: ethosuximide;   Drug: lamotrigine;   Drug: valproic acid
34 Active, not recruiting
Has Results
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
Conditions: Disseminated Neuroblastoma;   Recurrent Neuroblastoma
Interventions: Drug: ABT-751;   Procedure: quality-of-life assessment
35 Active, not recruiting Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Intervention: Other: laboratory biomarker analysis
36 Active, not recruiting Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
Conditions: Childhood Embryonal Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Extragonadal Germ Cell Tumor;   Childhood Malignant Ovarian Germ Cell Tumor;   Childhood Malignant Testicular Germ Cell Tumor;   Childhood Teratoma;   Ovarian Embryonal Carcinoma;   Ovarian Yolk Sac Tumor;   Stage II Malignant Testicular Germ Cell Tumor;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIC Ovarian Germ Cell Tumor;   Stage III Malignant Testicular Germ Cell Tumor;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIC Ovarian Germ Cell Tumor;   Testicular Choriocarcinoma and Yolk Sac Tumor;   Testicular Embryonal Carcinoma
Interventions: Procedure: conventional surgery;   Drug: cisplatin;   Drug: etoposide;   Biological: bleomycin sulfate;   Other: laboratory biomarker analysis
37 Recruiting A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Condition: Medulloblastoma
Interventions: Radiation: Craniospinal Irradiation with boost to the primary tumor site;   Drug: Cyclophosphamide;   Drug: Cisplatin;   Drug: Vincristine;   Drug: Vismodegib;   Drug: Pemetrexed;   Drug: Gemcitabine;   Other: Aerobic Training;   Other: Neurocognitive Remediation
38 Active, not recruiting Fludarabine-based Conditioning for Severe Aplastic Anemia
Condition: Anemia, Aplastic
Intervention: Drug: Cyclophosphamide
39 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Childhood Acute Basophilic Leukemia;   Childhood Acute Eosinophilic Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: thioguanine;   Drug: etoposide;   Other: laboratory biomarker analysis
40 Active, not recruiting Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Conditions: Adult Malignant Mesenchymoma;   Adult Rhabdomyosarcoma;   Alveolar Childhood Rhabdomyosarcoma;   Childhood Malignant Mesenchymoma;   Embryonal Childhood Rhabdomyosarcoma;   Embryonal-botryoid Childhood Rhabdomyosarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma
Interventions: Drug: irinotecan hydrochloride;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis;   Other: questionnaire administration

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years